Loading...

UCSF Coronavirus Response: UCSF is partnering with public agencies to address the rapidly evolving outbreak and protect our communities. The UCSF COVID-19 Resources Website provides guidance and information for our patients, faculty, staff, trainees and learners.

Kreshnik Zejnullahu, MD

Title(s)Assistant Professor, Medicine
SchoolSchool of Medicine
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Zejnullahu K, Santhosh L, Mourad M, Connor DM. Off Trail, On Track: an Exercise in Clinical Reasoning. J Gen Intern Med. 2019 Oct; 34(10):2282-2287. PMID: 31270781.
      View in: PubMed
    2. Friedlander TW, Graff JN, Zejnullahu K, Anantharaman A, Zhang L, Paz R, Premasekharan G, Russell C, Huang Y, Kim W, Aggarwal RR, Lin AM, Fong L, Alumkal JJ, Beer TM, Sharifi N, Alyamani M, Dittamore R, Small EJ, Paris PL, Ryan CJ. High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer. Clin Genitourin Cancer. 2017 12; 15(6):733-741.e1. PMID: 28655452.
      View in: PubMed
    3. Archana Anantharaman, Terence W. Friedlander, Christopher J. Welty, Kreshnik Zejnullahu, Jeffrey Hough, Matthew Edwards, Adam Jendrisak, Jerry Lee, Stephanie Greene, Priscilla Ontiveros, Ryon Graf, Angel Rodriguez, Mahipal Suraneni, Yipeng Wang, Mark Andrew Landers, Matthew R. Cooperberg, Peter Carroll, Ryan Vance Dittamore, Pamela Paris. Characterization of circulating tumor cells in patients with localized high risk prostate cancer, post-prostatectomy. Journal of Clinical Oncology. 2017 May 20; 35(15_suppl):e23055-e23055.
      View in: Publisher Site
    4. Terence W. Friedlander, Archana Anantharaman, Christopher Welty, Kreshnik Zejnullahu, Jeffrey Hough, Matthew Edwards, Adam Jendrisak, Jerry Lee, Stephanie Greene, Priscilla Ontiveros, Ryon Graf, Angel Rodriguez, Mahipal Suraneni, Yipeng Wang, Mark Andrew Landers, Matthew R. Cooperberg, Peter Carroll, Ryan Vance Dittamore, Pamela Paris. Characterization of circulating tumor cells in patients with localized high risk prostate cancer, post-prostatectomy. Journal of Clinical Oncology. 2017 Feb 20; 35(6_suppl):110-110.
      View in: Publisher Site
    5. Zejnullahu K, Arevalo MG, Ryan CJ, Aggarwal R. Approaches to minimize castration in the treatment of advanced prostate cancer. Urol Oncol. 2016 08; 34(8):368-74. PMID: 26944450.
      View in: PubMed
    6. Zejnullahu K, Khatami S, Manesh RS. Diffuse Alveolar Hemorrhage: Blood, Sweat and Tears. J Gen Intern Med. 2016 07; 31(7):812-3. PMID: 26892322.
      View in: PubMed
    7. Unni AM, Lockwood WW, Zejnullahu K, Lee-Lin SQ, Varmus H. Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma. Elife. 2015 Jun 05; 4:e06907. PMID: 26047463.
      View in: PubMed
    8. Cortot AB, Repellin CE, Shimamura T, Capelletti M, Zejnullahu K, Ercan D, Christensen JG, Wong KK, Gray NS, Jänne PA. Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway. Cancer Res. 2013 Jan 15; 73(2):834-43. PMID: 23172312.
      View in: PubMed
    9. Lockwood WW, Zejnullahu K, Bradner JE, Varmus H. Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins. Proc Natl Acad Sci U S A. 2012 Nov 20; 109(47):19408-13. PMID: 23129625.
      View in: PubMed
    10. K. Yonesaka, K. Zejnullahu, I. Okamoto, T. Satoh, F. Cappuzzo, J. Souglakos, J. Engelman, M. Varella-Garcia, K. Nakagawa, P. Jänne. OP 85 Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. European Journal of Cancer. 2011 Oct 1; 47:s10.
      View in: Publisher Site
    11. Yonesaka K, Zejnullahu K, Okamoto I, Satoh T, Cappuzzo F, Souglakos J, Ercan D, Rogers A, Roncalli M, Takeda M, Fujisaka Y, Philips J, Shimizu T, Maenishi O, Cho Y, Sun J, Destro A, Taira K, Takeda K, Okabe T, Swanson J, Itoh H, Takada M, Lifshits E, Okuno K, Engelman JA, Shivdasani RA, Nishio K, Fukuoka M, Varella-Garcia M, Nakagawa K, Jänne PA. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med. 2011 Sep 07; 3(99):99ra86. PMID: 21900593.
      View in: PubMed
    12. Ercan D, Zejnullahu K, Yonesaka K, Xiao Y, Capelletti M, Rogers A, Lifshits E, Brown A, Lee C, Christensen JG, Kwiatkowski DJ, Engelman JA, Jänne PA. Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor. Oncogene. 2010 Apr 22; 29(16):2346-56. PMID: 20118985.
      View in: PubMed
    13. Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E, Toschi L, Rogers A, Mok T, Sequist L, Lindeman NI, Murphy C, Akhavanfard S, Yeap BY, Xiao Y, Capelletti M, Iafrate AJ, Lee C, Christensen JG, Engelman JA, Jänne PA. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell. 2010 Jan 19; 17(1):77-88. PMID: 20129249.
      View in: PubMed
    14. Yonesaka K, Zejnullahu K, Lindeman N, Homes AJ, Jackman DM, Zhao F, Rogers AM, Johnson BE, Jänne PA. Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers. Clin Cancer Res. 2008 Nov 01; 14(21):6963-73. PMID: 18980991.
      View in: PubMed
    15. Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E, Holmes AJ, Choi HG, Kim J, Chiang D, Thomas R, Lee J, Richards WG, Sugarbaker DJ, Ducko C, Lindeman N, Marcoux JP, Engelman JA, Gray NS, Lee C, Meyerson M, Jänne PA. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res. 2008 Jul 01; 14(13):4275-83. PMID: 18594010.
      View in: PubMed
    16. Engelman JA, Zejnullahu K, Gale CM, Lifshits E, Gonzales AJ, Shimamura T, Zhao F, Vincent PW, Naumov GN, Bradner JE, Althaus IW, Gandhi L, Shapiro GI, Nelson JM, Heymach JV, Meyerson M, Wong KK, Jänne PA. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res. 2007 Dec 15; 67(24):11924-32. PMID: 18089823.
      View in: PubMed
    17. Kimio Yonesaka, Kreshnik Zejnullahu, Alison J. Homes, Bruce E. Johnson, Pasi A. Janne. C7-07: Presence of amphiregulin autocrine-loop predicts in vitro sensitivity of EGFR wild type NSCLC and HNSCC cell lines to gefitinib and cetuximab. Journal of Thoracic Oncology. 2007 Aug 1; 2(8):s382.
      View in: Publisher Site
    18. Jeffrey A. Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi, Courtney Hyland, Joon Oh Park, Neal Lindeman, Christopher-Michael Gale, Xiaojun Zhao, James Christensen, Rogers M. Rogers, Federico Cappuzzo, Tony Mok, Charles Lee, Johnson E. Bruce, Lewis C. Cantley, Pasi A. Jänne. D2-07: Mechanisms of activating PI3K signaling in lung cancers that become resistant EGFR tyrosine kinase inhibitors. Journal of Thoracic Oncology. 2007 Aug 1; 2(8):s396.
      View in: Publisher Site
    19. Joon Oh Park, Feng Zhao, Kreshnik Zejnullahu, Emmanuel Normant, Jeffrey A. Engelman, Bruce E. Johnson, Pasi A. Jänne. C1-07: IPI-504, a novel HSP90 inhibitor is effective in EGFR T790M and Non-T790M Gefitinib-resistant Lung Cancer Cell Lines. Journal of Thoracic Oncology. 2007 Aug 1; 2(8):s361.
      View in: Publisher Site
    20. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Jänne PA. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007 May 18; 316(5827):1039-43. PMID: 17463250.
      View in: PubMed
    21. Engelman JA, Mukohara T, Zejnullahu K, Lifshits E, Borrás AM, Gale CM, Naumov GN, Yeap BY, Jarrell E, Sun J, Tracy S, Zhao X, Heymach JV, Johnson BE, Cantley LC, Jänne PA. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J Clin Invest. 2006 Oct; 116(10):2695-706. PMID: 16906227.
      View in: PubMed
    Kreshnik's Networks
    Concepts
    Derived automatically from this person's publications.
    See all (109) concept(s)
    _
    Co-Authors
    People in Profiles who have published with this person.
    See all (10) people
    _
    Similar People
    People who share similar concepts with this person.
    See all (59) people
    _
    Same Department
    Search Department
    ↑